Hospital
Franciscan Health System
Franciscan Health System was paid $44.68M by Medicaid between Jan 2018 and Dec 2024, across 394 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 11% of everything it billed.
33Billing provider infoFRANCISCAN HEALTH SYSTEM
TACOMA, WA 98405
TACOMA, WA 98405
33aNPI1952309098assigned 07/12/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$44.68M
24GClaims1,756,663
24DCodes billed394
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Washington
Rank by total paid#13 of 49
Median peer was paid$20.06M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 273,404 | $6.91M | |
| 2019 | 267,762 | $6.86M | |
| 2020 | 231,510 | $5.54M | |
| 2021 | 273,263 | $6.98M | |
| 2022 | 276,097 | $7.08M | |
| 2023 | 243,259 | $6.20M | |
| 2024incomplete | 191,368 | $5.11M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 17,327 | 14,251 | $4.83M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.7% | 42,588 | 40,469 | $3.01M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.7% | 40,612 | 36,831 | $2.97M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.6% | 33,367 | 30,101 | $2.94M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 5.7% | 34,501 | 24,923 | $2.56M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 5.4% | 19,737 | 8,729 | $2.40M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.7% | 26,748 | 24,207 | $2.08M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.4% | 65,908 | 23,857 | $1.51M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 8,971 | 8,547 | $1.23M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 10,487 | 9,820 | $1.23M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 2.3% | 5,136 | 3,551 | $1.04M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 11,190 | 7,701 | $993K |
382 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 10,547 | $899K |
| 11045 | 1.8% | 3,938 | $824K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.6% | 3,942 | $729K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.6% | 35,668 | $708K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.5% | 2,166 | $686K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 2,115 | $599K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 1.3% | 3,981 | $565K |
| 93458 | 1.1% | 514 | $507K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 5,351 | $487K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 3,330 | $482K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.1% | 29,775 | $475K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 16,698 | $433K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 2,984 | $425K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,922 | $419K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,126 | $401K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,162 | $353K |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 2,472 | $352K |
| 97161 | <1% | 8,011 | $347K | |
| 58571 | <1% | 163 | $317K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,357 | $276K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,736 | $274K |
| G0378 | Hospital observation service, per hour | <1% | 7,744 | $251K |
| 70496 | <1% | 1,800 | $244K | |
| 29848 | <1% | 193 | $239K | |
| 97803 | <1% | 8,246 | $236K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 12,546 | $222K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,320 | $203K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,062 | $201K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,567 | $189K |
| 93017 | <1% | 2,290 | $187K | |
| 96415 | <1% | 903 | $167K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,836 | $162K |
| 97802 | <1% | 2,453 | $150K | |
| 62323 | <1% | 487 | $144K | |
| 93971 | <1% | 1,885 | $142K | |
| 76536 | <1% | 1,782 | $135K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14,170 | $134K |
| 29581 | <1% | 903 | $131K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,168 | $129K |
| 97162 | <1% | 3,401 | $127K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 580 | $127K |
| 84484 | <1% | 31,724 | $124K | |
| 76770 | <1% | 1,594 | $123K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 392 | $121K |
| 76801 | <1% | 2,246 | $114K | |
| 80053 | Comprehensive metabolic panel | <1% | 27,403 | $108K |
| 97165 | <1% | 2,786 | $104K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 28,194 | $97K |
| 80047 | <1% | 15,571 | $93K | |
| 96367 | <1% | 1,640 | $85K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,967 | $80K |
| 10060 | <1% | 379 | $75K | |
| 76937 | <1% | 2,556 | $74K | |
| 72100 | <1% | 4,145 | $70K | |
| 70498 | <1% | 1,880 | $67K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 10,186 | $62K |
| 71250 | <1% | 1,365 | $60K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 271 | $58K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,805 | $56K |
| 80076 | <1% | 19,700 | $55K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 380 | $54K |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 469 | $53K |
| 83605 | <1% | 10,036 | $50K | |
| 52356 | <1% | 25 | $48K | |
| 97116 | <1% | 4,385 | $47K | |
| 87040 | <1% | 7,853 | $46K | |
| 90715 | <1% | 2,522 | $45K | |
| 93970 | <1% | 505 | $44K | |
| 75574 | <1% | 258 | $43K | |
| 64483 | <1% | 105 | $42K | |
| 72141 | <1% | 333 | $41K | |
| 70486 | <1% | 1,664 | $41K | |
| 73560 | <1% | 4,303 | $41K | |
| 83880 | <1% | 9,240 | $40K | |
| 88307 | <1% | 2,526 | $39K | |
| 72040 | <1% | 1,822 | $39K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,278 | $39K |
| 97605 | <1% | 379 | $38K | |
| 36430 | <1% | 597 | $37K | |
| 73030 | <1% | 3,374 | $35K | |
| 73630 | <1% | 3,342 | $34K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 73,045 | $34K |
| 87641 | <1% | 3,698 | $33K | |
| 78264 | <1% | 171 | $32K | |
| 74018 | <1% | 1,582 | $31K | |
| 97597 | <1% | 1,362 | $31K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 692 | $31K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 230 | $30K |
| 12001 | <1% | 166 | $30K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,562 | $30K |
| 64721 | <1% | 57 | $29K | |
| 73130 | <1% | 3,031 | $28K | |
| 84145 | <1% | 3,219 | $27K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,490 | $27K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,514 | $27K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 706 | $26K |
| 73502 | <1% | 2,415 | $24K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 33 | $23K |
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | <1% | 12 | $22K |
| 97607 | <1% | 317 | $22K | |
| 73610 | <1% | 2,554 | $22K | |
| 71045 | Radiologic examination, chest; single view | <1% | 18,592 | $22K |
| 85379 | <1% | 4,741 | $22K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,446 | $22K |
| 36415 | Collection of venous blood by venipuncture | <1% | 27,531 | $21K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 32,349 | $21K |
| 76870 | <1% | 258 | $20K | |
| 30520 | <1% | 15 | $19K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 28,502 | $17K |
| 12002 | <1% | 109 | $17K | |
| 62321 | <1% | 57 | $15K | |
| 84112 | <1% | 2,278 | $15K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,129 | $15K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 58 | $15K |
| 64493 | <1% | 30 | $15K | |
| 73110 | <1% | 1,509 | $15K | |
| 72197 | <1% | 81 | $14K | |
| 80143 | <1% | 3,390 | $13K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,360 | $12K |
| 93923 | <1% | 205 | $11K | |
| 70491 | <1% | 104 | $10K | |
| 82565 | <1% | 17,996 | $10K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 21,684 | $10K |
| 76882 | <1% | 133 | $9K | |
| 95819 | <1% | 76 | $9K | |
| 43235 | <1% | 26 | $9K | |
| 72131 | <1% | 413 | $8K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 1,054 | $8K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 24 | $8K |
| 72070 | <1% | 442 | $7K | |
| 83735 | <1% | 8,650 | $7K | |
| 86850 | <1% | 5,590 | $7K | |
| 97166 | <1% | 234 | $7K | |
| 80179 | <1% | 3,252 | $7K | |
| 86923 | <1% | 769 | $7K | |
| 85610 | <1% | 32,011 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 21,418 | $6K |
| 73590 | <1% | 804 | $6K | |
| 43264 | <1% | 12 | $6K | |
| 93798 | <1% | 942 | $6K | |
| 82962 | <1% | 21,630 | $6K | |
| 49083 | <1% | 29 | $6K | |
| 82330 | <1% | 17,944 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 33,257 | $6K |
| 74183 | <1% | 41 | $5K | |
| 36569 | <1% | 13 | $5K | |
| 80050 | General health panel | <1% | 1,024 | $5K |
| 86900 | <1% | 6,711 | $5K | |
| 84702 | <1% | 8,837 | $5K | |
| 85027 | <1% | 7,725 | $5K | |
| 29125 | <1% | 44 | $5K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 161 | $5K |
| 72110 | <1% | 195 | $5K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 9,007 | $5K |
| 80051 | <1% | 14,203 | $4K | |
| A9270 | Non-covered item or service | <1% | 29,924 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,039 | $4K |
| 83690 | <1% | 19,043 | $4K | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 374 | $4K |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 13 | $4K |
| 76942 | <1% | 45 | $4K | |
| 81001 | <1% | 21,923 | $4K | |
| 80061 | Lipid panel | <1% | 1,240 | $4K |
| 59025 | Fetal non-stress test | <1% | 18 | $3K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 13 | $3K |
| 74174 | <1% | 48 | $3K | |
| 77001 | <1% | 52 | $3K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 43 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,538 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,156 | $3K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,863 | $3K |
| 86901 | <1% | 6,887 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 86 | $3K |
| 73562 | <1% | 129 | $3K | |
| 93308 | <1% | 16 | $3K | |
| 71271 | <1% | 38 | $3K | |
| 73221 | <1% | 26 | $3K | |
| 72050 | <1% | 85 | $3K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 2,928 | $2K |
| 96376 | <1% | 8,087 | $2K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 16 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,458 | $2K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 90 | $2K |
| 86140 | <1% | 2,107 | $2K | |
| 99152 | <1% | 3,498 | $2K | |
| 84703 | <1% | 6,116 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,856 | $2K |
| 84100 | <1% | 4,576 | $2K | |
| 29515 | <1% | 13 | $2K | |
| 82731 | <1% | 177 | $2K | |
| 71101 | <1% | 233 | $2K | |
| 87070 | <1% | 6,266 | $2K | |
| 74178 | <1% | 15 | $2K | |
| 82075 | <1% | 3,374 | $1K | |
| 81003 | <1% | 11,393 | $1K | |
| 82553 | <1% | 298 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,570 | $1K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 53 | $1K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 4,189 | $1K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 788 | $1K |
| 82947 | <1% | 14,097 | $1K | |
| 84156 | <1% | 1,828 | $1K | |
| 90686 | <1% | 177 | $1K | |
| 94060 | <1% | 41 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,326 | $1K |
| 85014 | <1% | 1,981 | $1K | |
| 74220 | <1% | 51 | $1K | |
| 82570 | <1% | 1,754 | $1K | |
| 87205 | <1% | 6,539 | $1K | |
| 85730 | <1% | 6,482 | $1K | |
| 94729 | <1% | 76 | $1K | |
| 74330 | <1% | 26 | $1K | |
| 85652 | <1% | 2,199 | $1K | |
| 83615 | <1% | 2,005 | $997.81 | |
| 73090 | <1% | 261 | $958.28 | |
| 96523 | <1% | 18 | $920.35 | |
| 87186 | <1% | 5,300 | $893.07 | |
| 82550 | <1% | 1,642 | $834.04 | |
| 82360 | <1% | 80 | $813.79 | |
| 81025 | <1% | 5,603 | $804.53 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 2,682 | $770.27 |
| 72128 | <1% | 79 | $754.74 | |
| 36591 | <1% | 34 | $752.51 | |
| 51798 | <1% | 76 | $746.46 | |
| 72170 | <1% | 304 | $722.38 | |
| 97035 | <1% | 103 | $705.27 | |
| 88342 | <1% | 1,401 | $691.27 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 26,613 | $660.45 |
| 94726 | <1% | 48 | $658.39 | |
| 0240U | <1% | 2,148 | $611.89 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 20,542 | $600.87 |
| 84550 | <1% | 1,780 | $597.41 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,251 | $529.31 |
| 84450 | <1% | 1,450 | $515.40 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 13,216 | $514.66 |
| J2704 | Injection, propofol, 10 mg | <1% | 18,467 | $508.84 |
| 36410 | <1% | 180 | $506.88 | |
| 97163 | <1% | 15 | $492.30 | |
| 76981 | <1% | 27 | $479.63 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,548 | $474.02 |
| 87077 | <1% | 2,422 | $472.35 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 2,864 | $471.58 |
| 73080 | <1% | 43 | $439.29 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 11,448 | $425.26 |
| 93325 | <1% | 94 | $409.64 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,829 | $399.73 |
| 84520 | <1% | 1,135 | $392.62 | |
| 94010 | <1% | 15 | $390.77 | |
| 85018 | <1% | 1,571 | $386.67 | |
| 82803 | <1% | 727 | $367.44 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,021 | $366.47 |
| 72114 | <1% | 13 | $355.48 | |
| 73140 | <1% | 27 | $340.23 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 89 | $333.24 |
| 84460 | <1% | 797 | $322.89 | |
| 88304 | <1% | 1,633 | $322.26 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 29,603 | $299.96 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15,703 | $299.74 |
| 87430 | <1% | 1,047 | $291.66 | |
| 73070 | <1% | 89 | $272.73 | |
| 84132 | <1% | 651 | $260.51 | |
| 88112 | <1% | 165 | $260.22 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,179 | $242.85 |
| 82728 | <1% | 142 | $238.72 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 390 | $233.85 |
| C1769 | Guide wire | <1% | 5,936 | $226.68 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 171 | $224.66 |
| G0008 | Administration of influenza virus vaccine | <1% | 178 | $217.90 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,930 | $212.99 |
| 88341 | <1% | 624 | $210.20 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 24 | $206.21 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 15,435 | $201.11 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,554 | $193.76 |
| 97598 | <1% | 23 | $186.66 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,083 | $176.27 |
| 84439 | <1% | 163 | $171.93 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 17,050 | $166.65 |
| 87808 | <1% | 518 | $144.46 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,784 | $142.92 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,762 | $133.32 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 12,837 | $132.95 |
| 74022 | <1% | 36 | $121.66 | |
| 83540 | <1% | 244 | $120.23 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 160 | $112.43 |
| 73060 | <1% | 13 | $111.96 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 602 | $109.88 |
| 82140 | <1% | 374 | $94.22 | |
| 83550 | <1% | 162 | $91.59 | |
| 82607 | <1% | 105 | $85.71 | |
| 51702 | <1% | 30 | $76.80 | |
| 87147 | <1% | 606 | $75.54 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 665 | $74.58 |
| 80164 | <1% | 19 | $74.28 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,040 | $72.44 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 2,745 | $67.42 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,924 | $66.28 |
| J3490 | Unclassified drugs | <1% | 123 | $62.49 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 4,284 | $57.57 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,951 | $57.54 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 3,497 | $52.98 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 194 | $51.56 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,819 | $49.12 |
| 72020 | <1% | 15 | $42.00 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,620 | $40.70 |
| C1729 | Catheter, drainage | <1% | 1,282 | $40.60 |
| 82248 | <1% | 65 | $36.56 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 3,784 | $31.51 |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 357 | $31.00 |
| 82150 | <1% | 119 | $29.95 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,333 | $29.75 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 4,251 | $29.10 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,243 | $28.16 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 669 | $24.88 |
| 87493 | <1% | 14 | $21.12 | |
| 0352U | <1% | 235 | $18.63 | |
| 87081 | <1% | 28 | $15.73 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 202 | $15.44 |
| 87428 | <1% | 177 | $12.81 | |
| 85651 | <1% | 19 | $11.55 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 310 | $5.25 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 489 | $4.78 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 465 | $4.22 |
| 82746 | <1% | 13 | $4.12 | |
| 85347 | <1% | 598 | $3.77 | |
| 87807 | <1% | 12 | $3.09 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,345 | $2.93 |
| 87653 | <1% | 13 | $2.77 | |
| C1730 | Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) | <1% | 38 | $2.76 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 120 | $2.41 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 183 | $2.20 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 449 | $1.72 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 646 | $0.52 |
| J1815 | Injection, insulin, per 5 units | <1% | 1,377 | $0.41 |
| 36416 | <1% | 375 | $0.31 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 220 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 751 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 87 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 38 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 407 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 262 | $0.00 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | 0% | 14 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 17 | $0.00 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 91 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 290 | $0.00 |
| C1766 | Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away | 0% | 27 | $0.00 |
| G8992 | Other physical or occupational therapy primary functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 29 | $0.00 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 55 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 36 | $0.00 |
| 88309 | 0% | 15 | $0.00 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 36 | $0.00 |
| 86880 | 0% | 15 | $0.00 | |
| 64494 | 0% | 15 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 31 | $0.00 |
| 88311 | 0% | 14 | $0.00 | |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 14 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 15 | $0.00 |
| 88331 | 0% | 30 | $0.00 | |
| 30140 | 0% | 13 | $0.00 | |
| 82010 | 0% | 14 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 65 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 345 | $0.00 |
| 88173 | 0% | 75 | $0.00 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 254 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 732 | $0.00 |
| C1874 | Stent, coated/covered, with delivery system | 0% | 14 | $0.00 |
| 76000 | 0% | 26 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 15 | $0.00 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 481 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 259 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 655 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 16 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 30 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 198 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 139 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 14 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 294 | $0.00 |
| J1598 | Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg | 0% | 45 | $0.00 |
| J2720 | Injection, protamine sulfate, per 10 mg | 0% | 28 | $0.00 |
| 96417 | 0% | 17 | $0.00 | |
| 85049 | 0% | 13 | $0.00 | |
| J2590 | Injection, oxytocin, up to 10 units | 0% | 24 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILCZEK, JOSEPH (CEO)
| Provider | Location | Paid |
|---|---|---|
| Franciscan Health System | Gig Harbor, WA | $14.31M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.